Caveolin gene expression predicts clinical outcomes for early-stage HER2-negative breast cancer treated with paclitaxel-based chemotherapy in the GeparSepto trial.
Terence M WilliamsAndreas SchneeweißChristian JackischChangxian ShenKarsten E WeberPeter Andreas FaschingCarsten DenkertJenny FurlanettoErnst HeinmöllerSabine SchmatlochThomas KarnChristopher W SzetoMarion T van MackelenberghValentina NekljudovaElmar StickelerPatrick Soon-ShiongChristian SchemThomas MairingerVolkmar MuellerFrederic MarméMichael UntchSibylle LoiblPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Our findings indicate high CAV1/2 expression is associated with worse DFS and OS in paclitaxel-treated patients. Conversely, in nab-paclitaxel-treated patients, high CAV1/2 expression is associated with increased pCR and no significant detriment to DFS or OS compared to low CAV1/2 expression.
Keyphrases
- newly diagnosed
- end stage renal disease
- gene expression
- poor prognosis
- early stage
- ejection fraction
- chronic kidney disease
- clinical trial
- prognostic factors
- randomized controlled trial
- dna methylation
- study protocol
- young adults
- lymph node
- advanced non small cell lung cancer
- patient reported
- epidermal growth factor receptor
- breast cancer risk